Health Care·Biotechnology·$3.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.35 | N/A | -11.46% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.35 | N/A | -11.46% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed a cautious approach in the current market environment. They emphasized their commitment to advancing their pipeline despite the lack of specific guidance.
Management did not provide specific revenue figures or guidance for the upcoming quarters.
The focus remains on ongoing research and development efforts.
Tango Therapeutics I reported a wider-than-expected loss per share, which may raise concerns among investors about its financial health. However, the stock reacted positively, increasing by 0.76%, likely due to investor optimism about the company's ongoing research initiatives. The lack of revenue data and forward guidance leaves some uncertainty about the company's immediate future.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AECOM
May 6, 2024